Search results
Results from the WOW.Com Content Network
Some scientific research suggests that vitamin B3, or niacin, may be helpful for managing ED. For example, a study in 2011 found that adult men with ED and dyslipidemia (abnormal amounts of lipids ...
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia). The American Heart Association recommends the descriptor ...
May improve erectile dysfunction. Nitric oxide is essential to penile function, helping to facilitate erections by signaling blood vessels to widen and smooth muscles in the penis to relax. ED can ...
Bicalutamide may cause sexual dysfunction, including decreased sex drive and erectile dysfunction. [8] However, the rates of these side effects with bicalutamide monotherapy are very low. [ 8 ] In the EPC trial, at 7.4 years follow-up, the rates of decreased libido and impotence were only 3.6% and 9.3% in the 150 mg/day bicalutamide monotherapy ...
Like all medications, ED drugs like sildenafil, tadalafil, vardenafil and avanafil do have the potential to cause side effects, and while they may be mild or nonexistent for some users, others may ...
Drug interactions are possible, but studies have not shown that these statins increase exposure to ciclosporin. [60] HIV-positive people taking protease inhibitors: Atorvastatin, pravastatin or fluvastatin: Negative interactions are more likely with other choices. [61] Persons taking gemfibrozil, a non-statin lipid-lowering drug Atorvastatin
Chemical structure of sildenafil (Viagra), the prototypical PDE5 inhibitor. A phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a vasodilating drug that works by blocking the degradative action of cGMP-specific phosphodiesterase type 5 (PDE5) on cyclic GMP in the smooth muscle cells lining the blood vessels supplying various tissues.
Intake of large doses (2.0 to 4.0 g/day) of long-chain omega−3 fatty acids as prescription drugs or dietary supplements are generally required to achieve significant (> 15%) lowering of triglycerides, and at those doses the effects can be significant (from 20% to 35% and even up to 45% in individuals with levels greater that 500 mg/dL).